Gewinn- und Verlustrechnung von Neurocrine Biosciences, Inc.

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 13,711,607 shares of the company's stock, valued at approximately $2,310,886,000. BlackRock Inc. owned 13.49% of Neurocrine Biosciences

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.

ABN AMRO Bank N.V. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,787 shares of the company's stock, valued at approximately $2,510,000. Other hedge funds also recently

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline).

INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes Mean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severity Approximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severity Findings reinforce that even patients with mild tardive dyskinesia movements are impacted and can experience meaningful improvements in movement severity, quality of life and functionality with INGREZZA treatment SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA® (valbenazine) capsules resulted in substantial and sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia (TD) movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline TD movement severity, including among participants with clinician-rated mild TD movements.

Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported ​in patients with the rare genetic disorder.

Cetera Investment Advisers increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 50.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,245 shares of the company's stock after purchasing an additional 6,756 shares